Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Lobe Sciences Ltd. . Lobe Sciences is a life sciences company focused on psychedelic medicines. To view the new research report, along with disclosures and disclaimers, or to download it in its entirety, please visit Sciences is a life sciences ...

Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Lobe Sciences Ltd. (OTC PINK:GTSIF) (CSE:LOBE). Lobe Sciences is a life sciences company focused on psychedelic medicines. To view the new research report, along with disclosures and disclaimers, or to download it in its entirety, please visit https:bit.ly3dIWXKe

Lobe Sciences is a life sciences company focused on psychedelic medicines and drug delivery to treat unmet needs representing multi-billion-dollar markets. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

In the Opportunity Research report, analyst Rob Goldman discusses how the Company's unique model and approach are poised to result in leadership status in a segment that is gaining significant traction in the US, Canada, and Europe.

Goldman commented, "In our view, Lobe Sciences appears poised to emerge as an innovative leader in the development of psychedelic medicines and drug delivery devices to treat a variety of unmet needs, representing multi-billion-dollar markets. Primary initial indications include mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD), using a psilocybin/N-Acetylcysteine (NAC) combination. The Company is also developing a unique Nasal Mist device that could be used with its flagship medicine under development or as a broad-based delivery system. Going forward, management will likely submit for FDA 510(k) clearance for this device, broadening its reach and generating revenue."

"Leveraging its five submitted patents and unique approach, GTSIF is currently engaged in a preclinical study at the University of Miami. Plus, the Nasal device is presently in the prototyping phase," noted Goldman.

"Management just completed an asset sale through a subsidiary vendor that will provide $32M in non-dilutive capital---an event and figure we do not believe is yet reflected in the current stock price. This event may ensure that GTSIF could largely self-fund development, M&A, and IP acquisition. Based on Lobe's market cap as compared to peer group valuations, its unique approach, IP submissions, and the value of upcoming milestones, we believe GTSIF could reach our price target in the next six months," concluded Goldman.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published company report on Lobe Sciences Ltd. ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Lobe Sciences Ltd. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $4500 by the Company for the production and distribution of research reports and associated press releases and distribution.

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com

SOURCE: Goldman Small Cap Research



View source version on accesswire.com:
https://www.accesswire.com/631626/Goldman-Small-Cap-Research-Publishes-New-Research-Report-on-Lobe-Sciences-Ltd

News Provided by ACCESSWIRE IA via QuoteMedia

The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings

The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings

The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases

The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

Keep reading... Show less
AgriFORCE

AgriFORCE Signs Definitive Contract to Deploy Its Proprietary Grow House Facility and IP in Barbados for Production of High Value Medical and Agricultural Crops

AgriFORCE Growing Systems Ltd. (“the Company") (NASDAQ: AGRI; AGRIW), an Intellectual Property (IP) -focused AgTech company dedicated to advancing sustainable cultivation and crop processing across multiple platforms, has signed a definitive contract with Humboldt Bliss, Ltd. (“Humboldt”), an agriculture and aquaculture business based in Barbados, West Indies. The contract is for the deployment of the AgriFORCE foundational IP – which includes a proprietary facility design, production and operation technologies and methods, and an automated growing system (the AgriFORCE “Grow House”) for the cultivation and sale of high value medical and agricultural products into the Caribbean and global pharmaceutical and agricultural markets.

Keep reading... Show less
Ayurcann Wins Two Leading Awards in Canada for Extraction Facility and Toll Processing Facility of the Year

Ayurcann Wins Two Leading Awards in Canada for Extraction Facility and Toll Processing Facility of the Year

Ayurcann Holdings Corp. ( CSE: AYUR OTCQB: CDCLF FSE:3ZQ0 ) (the "Company" or "Ayurcann") a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has won Extraction Facility of the Year and Toll Processing Facility of the Year at the 2021 GrowUp Awards Gala in Niagara Falls, Ontario, Canada.

Ayurcann is a growing extraction company continuously incorporating new and strategic business approaches to maintain their industry leading services. With an annual extraction capacity of up to 300,000 kg, Ayurcann can supply bulk or formulated THC and CBD products to industry leaders while also offering a competitive advantage through their white labelling services.

Keep reading... Show less
Adastra Holdings Reports Record Third Quarter Results

Adastra Holdings Reports Record Third Quarter Results

 Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) ("Adastra" or the "Company") has today filed its consolidated financial statements and related management discussion and analysis for the three and nine months ended September 30, 2021 and 2020, both of which are available at www.sedar.com .

Keep reading... Show less
AgriFORCE Signs Definitive Contract to Deploy Its Proprietary Grow House Facility and IP in Barbados for Production of High Value Medical and Agricultural Crops

AgriFORCE Signs Definitive Contract to Deploy Its Proprietary Grow House Facility and IP in Barbados for Production of High Value Medical and Agricultural Crops

Focused AgTech company dedicated to advancing sustainable cultivation and crop processing across multiple platforms, has signed a definitive contract with Humboldt Bliss, Ltd. ("Humboldt"), an agriculture and aquaculture business based in Barbados, West Indies. The contract is for the deployment of the AgriFORCE foundational IP which includes a proprietary facility design, production and operation technologies and methods, and an automated growing system (the AgriFORCE "Grow House") for the cultivation and sale of high value medical and agricultural products into the Caribbean and global pharmaceutical and agricultural markets.

Under the terms of the contract, AgriFORCE is responsible for constructing its proprietary facility and providing the full Standard Operating Procedures (SOPs) of the AgriFORCE Grow House and Humboldt is responsible for securing the project's land as well as operating the facility. Upon production, Humboldt has committed to remit an IP licensing, management services and equipment leasing fee to AgriFORCE for up to 14,300 pounds (6,500 kgs) of high value medical and agricultural crops per year. Based on AgriFORCE's internal financial modelling and current market index pricing, the Company believes that the contract represents $12.7M of annual recurring EBITDA. 1 As the initial contract is for a five-year-term, the Company believes this represents more than $63M in EBITDA 1 over the initial term and with two five-year automatic renewals, it anticipates the total contract EBITDA 1 could be up to approximately $190 million. The contract will be backed by a rolling $5 million performance bond maintained by Humboldt.

Keep reading... Show less
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Greenrose Acquisition Corp. - GNRS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Greenrose Acquisition Corp. - GNRS

Pomerantz LLP is investigating claims on behalf of investors of Greenrose Acquisition Corp. ("Greenrose" or the "Company") (OTCMKTS: GNRS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Greenrose and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Keep reading... Show less

Top News

Related News